135 related articles for article (PubMed ID: 12074541)
1. The development of polyplex-based DNA vaccines.
Howard KA; Alpar HO
J Drug Target; 2002 Mar; 10(2):143-51. PubMed ID: 12074541
[TBL] [Abstract][Full Text] [Related]
2. Current status of DNA vaccines and their route of administration.
Alpar HO; Bramwell VW
Crit Rev Ther Drug Carrier Syst; 2002; 19(4-5):307-83. PubMed ID: 12661697
[TBL] [Abstract][Full Text] [Related]
3. Micro- and nanoparticulates for DNA vaccine delivery.
Farris E; Brown DM; Ramer-Tait AE; Pannier AK
Exp Biol Med (Maywood); 2016 May; 241(9):919-29. PubMed ID: 27048557
[TBL] [Abstract][Full Text] [Related]
4. Cationic polymers that enhance the performance of HbsAg DNA in vivo.
Bos GW; Kanellos T; Crommelin DJ; Hennink WE; Howard CR
Vaccine; 2004 Dec; 23(4):460-9. PubMed ID: 15530694
[TBL] [Abstract][Full Text] [Related]
5. Formulation of a microparticle carrier for oral polyplex-based DNA vaccines.
Howard KA; Li XW; Somavarapu S; Singh J; Green N; Atuah KN; Ozsoy Y; Seymour LW; Alpar HO
Biochim Biophys Acta; 2004 Sep; 1674(2):149-57. PubMed ID: 15374619
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of a subcutaneously administered block/homo-mixed polyplex micelle as a carrier for DNA vaccination in a mouse tumor model.
Cui L; Osada K; Imaizumi A; Kataoka K; Nakano K
J Control Release; 2015 May; 206():220-31. PubMed ID: 25819159
[TBL] [Abstract][Full Text] [Related]
7. Chlamydia vaccines: strategies and status.
Igietseme JU; Black CM; Caldwell HD
BioDrugs; 2002; 16(1):19-35. PubMed ID: 11908999
[TBL] [Abstract][Full Text] [Related]
8. Delivery of DNA vaccines: an overview on the use of biodegradable polymeric and magnetic nanoparticles.
Xiang SD; Selomulya C; Ho J; Apostolopoulos V; Plebanski M
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(3):205-18. PubMed ID: 20391461
[TBL] [Abstract][Full Text] [Related]
9. DNA vaccines for biodefence.
Garmory HS; Perkins SD; Phillpotts RJ; Titball RW
Adv Drug Deliv Rev; 2005 Jun; 57(9):1343-61. PubMed ID: 15935877
[TBL] [Abstract][Full Text] [Related]
10. Oral delivery of micro-encapsulated DNA vaccines.
Jones DH; Clegg JC; Farrar GH
Dev Biol Stand; 1998; 92():149-55. PubMed ID: 9554269
[TBL] [Abstract][Full Text] [Related]
11. Delivery systems for gene-based vaccines.
Dubensky TW; Liu MA; Ulmer JB
Mol Med; 2000 Sep; 6(9):723-32. PubMed ID: 11071268
[TBL] [Abstract][Full Text] [Related]
12. Induction of immunity using oral DNA vaccines expressing the measles virus nucleocapsid protein.
Fooks AR; Sharpe SA; Shallcross JA; Clegg JC; Cranage MP
Dev Biol (Basel); 2000; 104():65-71. PubMed ID: 11713826
[TBL] [Abstract][Full Text] [Related]
13. Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules.
Eo SK; Gierynska M; Kamar AA; Rouse BT
J Immunol; 2001 May; 166(9):5473-9. PubMed ID: 11313385
[TBL] [Abstract][Full Text] [Related]
14. DNA vaccines against enteric infections.
Herrmann JE
Vaccine; 2006 May; 24(18):3705-8. PubMed ID: 16095769
[TBL] [Abstract][Full Text] [Related]
15. Electroporation-based DNA immunisation: translation to the clinic.
Luxembourg A; Evans CF; Hannaman D
Expert Opin Biol Ther; 2007 Nov; 7(11):1647-64. PubMed ID: 17961089
[TBL] [Abstract][Full Text] [Related]
16. Immunization strategies to augment oral vaccination with DNA and viral vectors expressing HIV envelope glycoprotein.
Wierzbicki A; Kiszka I; Kaneko H; Kmieciak D; Wasik TJ; Gzyl J; Kaneko Y; Kozbor D
Vaccine; 2002 Jan; 20(9-10):1295-307. PubMed ID: 11818148
[TBL] [Abstract][Full Text] [Related]
17. Oral vaccination of mice with Trichinella spiralis nudix hydrolase DNA vaccine delivered by attenuated Salmonella elicited protective immunity.
Liu P; Wang ZQ; Liu RD; Jiang P; Long SR; Liu LN; Zhang XZ; Cheng XC; Yu C; Ren HJ; Cui J
Exp Parasitol; 2015 Jun; 153():29-38. PubMed ID: 25733024
[TBL] [Abstract][Full Text] [Related]
18. Recent developments in mucosal delivery of pDNA vaccines.
Barnes AG; Barnfield C; Brew R; Klavinskis LS
Curr Opin Mol Ther; 2000 Feb; 2(1):87-93. PubMed ID: 11249656
[TBL] [Abstract][Full Text] [Related]
19. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines.
He Q; Martinez-Sobrido L; Eko FO; Palese P; Garcia-Sastre A; Lyn D; Okenu D; Bandea C; Ananaba GA; Black CM; Igietseme JU
Immunology; 2007 Sep; 122(1):28-37. PubMed ID: 17451464
[TBL] [Abstract][Full Text] [Related]
20. DNA vaccines: vector design, delivery, and antigen presentation.
Feltquate DM
J Cell Biochem Suppl; 1998; 30-31():304-11. PubMed ID: 9893284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
